Sulfate salt of the free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, pharmaceutical formulations, methods of manufacture and uses thereof
The present invention relates to the field of anti-viral active agents, particularly to salts, more particularly to a maleate salt of the free base of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, to pharmaceutical formulations thereof as well as to methods for the production of these salts. The present invention also relates to the use of theses salts and of respective pharmaceutical formulations thereof in methods of treatment and/or prevention of human herpes simplex virus infections, particulary infections caused by HSV-1 and HSV-2.
1. A sulfate salt of the free base of N-[5-(amino-sulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide,
wherein said sulfate salt is characterized by having characteristic XRPD peaks at 5.6, 13.1, 19.7, 20.1, 22.1, 23.2 and 26.1 2theta when determined by using a compendial method as per “Ph. Eur” and/or “USP” methods.
2. The sulfate salt of claim 1 , wherein said sulfate salt is characterized by solubility in water of about 0.175 mg/mL when determined by using a compendial method as per “Ph. Eur” and/or “USP” methods.
3. A pharmaceutical composition comprising the sulfate salt of claim 1 , wherein said pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient.
4. The pharmaceutical composition of claim 3 , further comprising another pharmaceutically active ingredient selected from the group consisting of anti-inflammatory agents, anti-viral agents, centrally and peripherally acting analgesics, and anesthetics.
5. The pharmaceutical composition of claim 3 , further comprising an ultraviolet radiation blocking agent selected from the group consisting of octisalate, titanium dioxide, zinc oxide, PABA, homosalate, trolamine salicylate, dioxybenzone, sulisobenzone, oxybenzone, avobenzone, ecasmule, meradimate, cinoxate, and octocrylene.
6. A topical pharmaceutical formulation comprising the sulfate salt of claim 1 suitable for use in patch administration, creams, ointments, salves, gels, skin lotions, wax formulations, lipsticks, tonics, mousses, foam, films, emulsions, paste, solutions, oils, or lipogels.
7. The topical pharmaceutical formulation of claim 6 , wherein the said sulfate salt is present in an amount of 5.0% w/w, and wherein the topical pharmaceutical formulation is either an ointment, a gel, or a cream.
8. A method of treating or preventing herpes virus infections comprising the administration of the sulfate salt of claim 1 .
9. A method of treating or preventing herpes virus infections comprising administration of the pharmaceutical composition of claim 3 .
10. A method comprising:
topical administration of the sulfate salt of claim 1 to a subject in need thereof, wherein said topical administration comprises the application to skin and mucosal surfaces.
11. The pharmaceutical composition of claim 4 , wherein said anesthetics are local anesthetics.
12. A method of treating or preventing herpes virus infections comprising administration of the pharmaceutical composition of claim 7 , wherein said pharmaceutical composition is administered 5 times a day over a period of 4 days.